ExCellThera Announces Positive Phase 2 Study Results from UM171 Cell Therapy in Patients with High-risk Leukemias and Myelodysplasias at American Society of Hematology (ASH) 2023 Annual Meeting
December 12, 2023 07:00 ET
|
ExCellThera
50 patients evaluated in Phase 2 studies; ExCellThera’s UM171 showed excellent clinical outcomes for this high-risk leukemia/myelodysplasia cohort
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
December 12, 2023 05:15 ET
|
ADC Therapeutics SA
Combination demonstrated clinically meaningful benefit in r/r FL patients with 96% overall response rate and 85% complete response rate LAUSANNE, Switzerland, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ADC...
Be The Match Announces Winners of 2023 NMDP/Be The Match Awards
November 27, 2023 10:21 ET
|
Be The Match
NMDP/Be The Match® announces the recipients of its annual NMDP/Be The Match Awards at The ONE Forum 2023.
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference
November 09, 2023 16:01 ET
|
Vor Biopharma
Primary neutrophil engraftment of trem-cel achieved in all seven patients treated to dateAll three patients receiving multiple Mylotarg™ doses exhibited hematologic protection, further validating Vor...
Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update
November 07, 2023 16:05 ET
|
Vor Biopharma
Next trem-cel (VOR33) clinical data update expected by Relapse After Transplant and Cellular Therapy (HSCT2) Conference Nov 10-11Three oral abstracts and two poster presentations accepted at ASH 2023...
Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline
November 07, 2023 07:30 ET
|
Adaptive Biotechnologies
Data generated by Adaptive’s next-generation sequencing-based MRD assay will support the development and commercialization of investigational medicines for hematologic malignancies SEATTLE, Nov. 07,...
ExCellThera announces new UM171 data to be presented at ASH 2023
November 03, 2023 08:15 ET
|
ExCellThera
ExCellThera announced today several UM171 presentations at ASH2023, including new data from Phase 2 studies in high-risk blood cancer patients
Vor Bio to Participate in Upcoming Investor Conferences
November 03, 2023 08:00 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
The International Myeloma Foundation is Creating an Award-Winning Tool for Nurses to Improve Myeloma Patient Outcomes in Underserved Communities
November 02, 2023 13:15 ET
|
International Myeloma Foundation
The International Myeloma Foundation wins the 2023 Sanofi HealthEquity Accelerator Award for their program which empowers nurses and tackles disparities.
Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio’s Novel eHSC and CAR-T Platform
November 02, 2023 09:01 ET
|
Vor Biopharma
Three oral and two poster presentations accepted by ASHCompany to host call featuring Sarah K. Tasian, MD, Associate Professor of Pediatrics at the University of Pennsylvania School of Medicine and...